7.05
+0.09
+(1.29%)
At close: 4:00:00 PM EDT
6.96
-0.09
(-1.28%)
After hours: 4:53:04 PM EDT
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | -0.19 | 0.54 | 0.11 | 0.65 |
| Low Estimate | -0.24 | -0.18 | -0.99 | -0.04 |
| High Estimate | -0.15 | 2.29 | 1.97 | 1.24 |
| Year Ago EPS | -0.4 | -0.48 | -2.28 | 0.11 |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 7 |
| Avg. Estimate | 16.96M | 21.07M | 85.06M | 161.7M |
| Low Estimate | 14.4M | 18.2M | 57.8M | 118.4M |
| High Estimate | 20.8M | 24.4M | 99.4M | 212M |
| Year Ago Sales | 3.42M | 4.45M | 23.61M | 85.06M |
| Sales Growth (year/est) | 395.13% | 373.67% | 260.23% | 90.10% |
Earnings History
| Currency in USD | 3/31/2024 | 6/30/2024 | 9/30/2024 | 12/31/2024 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.44 | -0.41 | -0.4 |
| EPS Actual | -0.4 | -0.48 | -0.69 | -0.69 |
| Difference | 0.08 | -0.04 | -0.28 | -0.29 |
| Surprise % | 16.32% | -9.92% | -68.29% | -73.12% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.19 | 0.54 | 0.11 | 0.65 |
| 7 Days Ago | 0.56 | -0.15 | 0.04 | 0.89 |
| 30 Days Ago | 0.56 | -0.15 | 0.04 | 0.89 |
| 60 Days Ago | 0.48 | -0.16 | -0.04 | 0.87 |
| 90 Days Ago | 0.09 | -0.17 | -0.32 | 0.82 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 3 | 4 | 5 | 1 |
| Up Last 30 Days | 3 | 4 | 5 | 1 |
| Down Last 7 Days | 2 | -- | 1 | 5 |
| Down Last 30 Days | 2 | -- | 1 | 5 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ZVRA | 53.57% | 213.39% | 104.93% | 480.32% |
| S&P 500 | 6.79% | 5.59% | 9.06% | 14.11% |
Upgrades & Downgrades
| Maintains | Canaccord Genuity: Buy to Buy | 3/13/2025 |
| Maintains | Guggenheim: Buy to Buy | 3/13/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/13/2025 |
| Maintains | Citizens Capital Markets: Market Outperform to Market Outperform | 3/12/2025 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 3/12/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/20/2024 |
Related Tickers
SNDX Syndax Pharmaceuticals, Inc.
11.05
-2.47%
STOK Stoke Therapeutics, Inc.
7.56
-2.45%
XFOR X4 Pharmaceuticals, Inc.
0.1953
-6.11%
DAWN Day One Biopharmaceuticals, Inc.
6.76
-5.98%
TYRA Tyra Biosciences, Inc.
8.61
-0.58%
MGTX MeiraGTx Holdings plc
5.32
-2.39%
PBYI Puma Biotechnology, Inc.
2.8800
-2.70%
TVTX Travere Therapeutics, Inc.
14.57
-2.28%
FBIO Fortress Biotech, Inc.
1.5000
-1.32%
LENZ LENZ Therapeutics, Inc.
23.06
-3.47%